LCID
Lucid Group, Inc.
LCID offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
MHK
Mohawk Industries, Inc.
MHK has a slight edge over LCID overall, supported by lower modeled downside.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
MHK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Healthy |
MHK's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
MHK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.3x | $79.26 | -46% |
| Fair | 15x | $126 | -14% |
| Forward | 16x | $147 | — |
| Current | 17x | $147 | — |
| Expensive | 21x | $182 | +24% |
Historical ranges are pointers, not guarantees.
MHK's PE is in its expensive range at 17x. On analysts' estimates for next year's earnings, today's price would be 16x, in its fair range.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
MHK Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect MHK's earnings, revenue and profitability to hold roughly steady.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
MHK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.11 | +6.8% |
| Q3 2026 | $8.53 | +27% |
| Q2 2026 | $7.56 | +0.4% |
| Q1 2026 | $6.68 | -13% |
| Q4 2025 | $5.93 | -27% |
| Q3 2025 | $6.73 | -24% |
| Q2 2025 | $7.53 | +$13.17 |
| Q1 2025 | $7.65 | +$14.17 |
| Q4 2024 | $8.14 | +$15.04 |
MHK has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over MHK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
MHK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8B | +1% |
| Q2 2026 | $3B | +6.8% |
| Q1 2026 | $2.7B | +8% |
| Q4 2025 | $2.7B | +2.4% |
| Q3 2025 | $2.8B | +1.4% |
| Q2 2025 | $2.8B | 0% |
| Q1 2025 | $2.5B | -5.7% |
| Q4 2024 | $2.6B | +1% |
MHK's revenue has grown year over year for six quarters in a row: $2.8B last quarter, up 1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.7% | +1.8 points |
| Q2 2026 | 8.5% | +1.8 points |
| Q1 2026 | 4.1% | +0.3 points |
| Q4 2025 | 2.5% | -2.1 points |
| Q3 2025 | 5% | -2.8 points |
| Q2 2025 | 6.7% | -0.9 points |
| Q1 2025 | 3.8% | -1.7 points |
| Q4 2024 | 4.6% | -1.8 points |
MHK has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
MHK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $390.3M | +26% |
| Q2 2026 | $228.2M | +81% |
| Q1 2026 | $7.8M | +$93.2M |
| Q4 2025 | $265.2M | +12% |
| Q3 2025 | $310.3M | +52% |
| Q2 2025 | $126.1M | -11% |
| Q1 2025 | -$85.4M | -188% |
| Q4 2024 | $236.2M | +322% |
MHK has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
MHK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -900K shares |
| 1 year | -3.7% | -2.3M shares |
| 3 years | -5.8% | -3.7M shares |
| 5 years | -13% | -8.9M shares |
| Available history | -17% | -12.3M shares |
MHK has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $260.9M |
| Q2 2026 | $59.9M |
| Q1 2026 | $64.7M |
| Q4 2025 | $41.1M |
| Q3 2025 | $40.6M |
| Q2 2025 | $42.6M |
| Q1 2025 | $25.5M |
| Q4 2024 | $74.9M |
MHK spent $427M buying back its own shares over the past year, up 132% from the year before.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MHK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.8x | Very low |
| Q2 2026 | 0.9x | Very low |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 1.0x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.2x | Healthy |
MHK's net debt is less than a year of its operating earnings (EBITDA), down from 1.2 years a year ago.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
MHK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.4 | Neutral |
| Stochastic | 84.5 | Overbought |
MHK's weekly RSI is 64 (neutral) and its Stochastic is 85 (overbought).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
MHK PE vs Consumer Cyclical Sector
| Metric | MHK | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 18x | 4.6% below |
| PE % | 69 | 47 | 22 pts above |
MHK is trading at 17x earnings, in line with the Consumer Cyclical sector's median of 18x.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
MHK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $131.4 | 12% above |
| 20 week MA | $127.9 | 15% above |
| 50 week MA | $117.5 | 25% above |
| 100 week MA | $116.8 | 26% above |
| 200 week MA | $115.1 | 27% above |
MHK has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
MHK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $134.4 | $138.7 | +3.2% |
| 2021 | $138.7 | $171.2 | +23% |
| 2022 | $171.2 | $98.0 | -43% |
| 2023 | $98.0 | $103.5 | +5.7% |
| 2024 | $103.5 | $118.8 | +15% |
| 2025 | $118.8 | $110.2 | -7.2% |
| 2026 YTD | $110.2 | $146.6 | +33% |
MHK has the edge over LCID on returns for 2026, with the stronger performance.